Retrophin's (RTRX) RE-024 Granted EC Orphan Drug Designation for the Treatment of PKAN
Tweet Send to a Friend
Retrophin, Inc. (NASDAQ: RTRX) announced that the European Commission has granted orphan drug designation to RE-024, the Company’s novel investigational ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
